Top

Published in:

01-09-2015 | Case Report

Black hole restenosis after drug-eluting stent implantation for in-stent restenosis: potential mechanism and optimal strategy

Authors: Yoritaka Otsuka, Takashi Murata, Michiaki Kono, Hiroki Imoto, Taku Koyama, Keita Nakamura, Sunao Kadama, Hiroo Noguchi, Taro Saito

Published in: Heart and Vessels | Issue 5/2015

Abstract

In-stent restenosis (ISR) has long remained as the major limitation of coronary stenting. The use of drug-eluting stent (DES) reduces the risk of repeat revascularization without an increase of death and myocardial infarction, compared to the standard bare metal stents. DES has also demonstrated markedly to reduce ISR for complex lesions. However, ISR after DES implantation still occurs and optimal treatment for ISR after DES has not been established. Herein, we report 3 cases with black hole restenosis confirmed by intravascular ultrasound at the site of overlapped DES and discuss potential mechanism and optimal strategy for this phenomenon.

Morice MC, Serruys PW, Sousa JE, Fajadet J, BanHayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R, RAVEL Study Group (2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773–1780CrossRefPubMed

Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE, SIRIUS Investigators (2003) Sirolimus-eluting stents versus standard stents in patientswith stenosis in a native coronary artery. N Engl J Med 349:1315–1323CrossRefPubMed

Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R (2010) In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 56:1897–1907CrossRefPubMed

Farooq V, Gogas BD, Serruys PW (2011) Restenosis: delineating the numerous causes of drug-eluting stent restenosis. Circ Cardiovasc Interv 4:195–205CrossRefPubMed

Abe M, Kimura T, Morimoto T, Taniguchi T, Yamanaka F, Nakao K, Yagi N, Kokubu N, Kasahara Y, Kataoka Y, Otsuka Y, Kawamura A, Miyazaki S, Nakao K, Horiuchi K, Ito A, Hoshizaki H, Kawaguchi R, Setoguchi M, Inada T, Kishi K, Sakamoto H, Morioka N, Imai M, Shiomi H, Nonogi H, Mitsudo K, j-Cypher Registry Investigators (2010) Sirolimus-eluting stent versus balloon angioplasty for sirolimus-eluting stent restenosis: Insights from the j-Cypher Registry. Circulation 122:42–51CrossRefPubMed

Habara S, Mitsudo K, Kadota K, Goto T, Fujii S, Yamamoto H, Katoh H, Oka N, Fuku Y, Hosogi S, Hirono A, Maruo T, Tanaka H, Shigemoto Y, Hasegawa D, Tasaka H, Kusunose M, Otsuru S, Okamoto Y, Saito N, Tsujimoto Y, Eguchi H, Miyake K, Yoshino M (2011) Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovasc Interv 4:149–154CrossRefPubMed

Habara S, Iwabuchi M, Inoue N, Nakamura S, Asano R, Nanto S, Hayashi Y, Shiode N, Saito S, Ikari Y, Kimura T, Hosokawa J, Nakamura M, Kotani J, Kozuma K, Mitsudo K (2013) A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. Am Heart J 166:527–533CrossRefPubMed

Nakano M, Otsuka F, Yahagi K, Sakakura K, Kutys R, Ladich ER, Finn AV, Kolodgie FD, Virmani R (2013) Human autopsy study of drug-eluting stents restenosis: histomorphological predictors and neointimal characteristics. Eur Heart J 34:3304–3313CrossRefPubMedCentralPubMed

Koshy SK, Kleiman NS, George LK, Misra V, Hillegass WB, Brott BC (2008) Vascular changes and black hole phenomenon after coronary brachytherapy: a pathologically distinct entity. J Invasive Cardiol 20:560–562PubMed

10.

Costa MA, Simon DI (2005) Molecular basis of restenosis and drug-eluting stents. Circulation 111:2257–2273CrossRefPubMed

11.

Costa MA, Sabate M, Angiolillo DJ, Jimenez-Quevedo P, Teirstein P, Carter A, Leon MB, Moses J, Zenni M, Yakubov S, Guzman LA, Gilmore P, Macaya C, Bass TA (2006) Intravascular ultrasound characterization of the “black hole” phenomenon after drug-eluting stent implantation. Am J Cardiol 97:203–206CrossRefPubMed

12.

Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369:667–678CrossRefPubMed

13.

Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T, Shiode N, Namura M, Sone T, Oshima S, Nishikawa H, Hiasa Y, Hayashi Y, Nobuyoshi M, Mitudo K, j-Cypher Registry Investigators (2012) Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation 125:584–591CrossRefPubMed

14.

Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R (2006) Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48:193–202CrossRefPubMed

15.

Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R (2007) Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115:2435–2441CrossRefPubMed

16.

Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD (2004) Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109:701–705CrossRefPubMed

17.

Carter AJ, Aggarwal M, Kopia GA, Tio F, Tsao PS, Kolata R, Yeung AC, Llanos G, Dooley J, Falotico R (2004) Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res 63:617–624CrossRefPubMed

18.

Otsuka Y, Nakamura M, Kokubu N, Tonooka A, Inoue K, Higami T (2012) Diffuse in-stent restenosis of CYPHER^® stent due to hypersensitivity reaction confirmed by pathohistological findings. Heart Vessels 27:110–113CrossRefPubMed

19.

Oikawa Y, Yajima J, Costa MA, Matsuno S, Akabane M, Funada R, Inaba T, Nakagawa Y, Nakamura M, Nagashima K, Kirigaya H, Ogasawara K, Sawada H, Aizawa T (2010) Intravascular ultrasound, angioscopic and histopathological characterisation of heterogeneous patterns of restenosis after sirolimus-eluting stent implantation: insights into potential “thromborestenosis” phenomenon. EuroIntervention 6:380–387CrossRefPubMed

20.

Goto K, Shiode N, Shirota K, Fukuda Y, Kitamura F, Tominaga K, Kato Y, Miura H, Inoue K, Nobuyoshi M (2009) Pathological finding of sirolimus-eluting stent (SES) restenosis lesion with black hole appearance on intravascular ultrasound. Circ J 73:1969–1971CrossRefPubMed

21.

Linares Vicente JA, Lukic A, Gonzalo López N, Ruiz Arroyo JR (2012) Atypical “black hole” phenomenon after treatment of sirolimus stent restenosis with a paclitaxel-coated balloon. EuroIntervention 7:1479CrossRefPubMed

22.

Kurita T, Terashima M, Suzuki T (2012) Serial optical coherence tomography imaging of the “black-hole” phenomenon by intravascular ultrasound following sirolimus-eluting stent implantation. EuroIntervention 7:1480–1481CrossRefPubMed

23.

Landmesser U (2012) Optical coherence tomography (OCT) evaluation after coronary stenting: the “black hole” and other low OCT signal-intensity areas. EuroIntervention 7:1367–1371CrossRefPubMed

24.

Farb A, Kolodgie FD, Hwang JY, Burke AP, Tefera K, Weber DK, Wight TN, Virmani R (2004) Extracellular matrix changes in stented human coronary arteries. Circulation 110:940–947CrossRefPubMed

25.

Dörr O, Liebetrau C, Wiebe J, Hecker F, Rixe J, Möllmann H, Hamm C, Nef H (2014) Bioresorbable scaffolds for the treatment of in-stent restenosis. Heart Vessels. doi:10.1007/s00380-013-0464-5 PubMed

Title: Black hole restenosis after drug-eluting stent implantation for in-stent restenosis: potential mechanism and optimal strategy
Authors: Yoritaka Otsuka
Takashi Murata
Michiaki Kono
Hiroki Imoto
Taku Koyama
Keita Nakamura
Sunao Kadama
Hiroo Noguchi
Taro Saito
Publication date: 01-09-2015
Publisher: Springer Japan
Published in: Heart and Vessels / Issue 5/2015
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-014-0528-1

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Black hole restenosis after drug-eluting stent implantation for in-stent restenosis: potential mechanism and optimal strategy

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2015

High incidence and severity of periodontitis in patients with Marfan syndrome in Japan

Impact of combined lipid lowering with blood pressure control on coronary plaque regression: rationale and design of MILLION study

Possible role of fibroblast growth factor 21 on atherosclerosis via amelioration of endoplasmic reticulum stress-mediated apoptosis in apoE−/− mice

Effects of flecainide on left ventricular pressure gradient and symptoms in obstructive hypertrophic cardiomyopathy: a comparison of flecainide and disopyramide

Development of new risk score for pre-test probability of obstructive coronary artery disease based on coronary CT angiography

Lack of association between peri-procedural myocardial damage and CYP2C19 gene variant in elective percutaneous coronary intervention

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page